Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Why hereditary angioedema could become Intellia Therapeutics’ biggest CRISPR validation test Find out how Intellia’s lonvo-z Phase 3 data could reshape HAE treatment and investor sentiment around in vivo CRISPR. bySoujanya RaviJune 15, 2026